On April 20, 2022 Immune-Onc Therapeutics, Inc. ("Immune-Onc"), a private, clinical-stage cancer immunotherapy company developing novel biotherapeutics targeting myeloid checkpoints, reported the selection of IO-106, a first-in-class myeloid and stromal checkpoint inhibitor targeting the inhibitory receptor, Leukocyte‐Associated Immunoglobulin‐Like Receptor 1 (LAIR1), for clinical development (Press release, Immune-Onc Therapeutics, APR 20, 2022, View Source [SID1234612598]). The Company will present a scientific poster on the therapeutic potential of anti-LAIR1 antibodies at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) Tumor Immune Microenvironment: A Holistic Approach Workshop on April 21st in San Diego, CA.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

LAIR1 is an immune inhibitory receptor expressed on lymphocytes and myeloid cells that correlates with worse survival in several cancers. LAIR1 is activated by collagen which is highly abundant in the stroma of many solid tumor types and is thought to contribute to immune suppression. The data being presented suggest that LAIR1 antagonist antibodies reverse collagen-mediated immune suppression on T cells and myeloid cells in the solid tumor microenvironment, thereby promoting anti-tumor immunity.

"IO-106 is now the third clinical candidate in our pipeline and a testament to the depth and rigor of our science," said Charlene Liao, Ph.D., chief executive officer of Immune-Onc. "Immune-Onc was founded on groundbreaking science that first illuminated the role of the previously unexplored LILRB family of myeloid checkpoints in cancer. This research has rapidly advanced a completely new field of study and class of cancer immunotherapy that goes beyond T cells to overcome immune resistance and the limitations of current treatment options. We are very excited about potential development opportunities for IO-106 and look forward to sharing our progress in the near future."

ABOUT LAIR1

LAIR1 is an immune inhibitory receptor of the Leukocyte Immunoglobulin-Like Receptor subfamily B (LILRB) and is expressed on lymphocytes and myeloid cells. Research shows that LAIR1 expression correlates with worse survival in several cancers. LAIR1 is activated by collagen, which is highly abundant in the stroma of many solid tumor types and is thought to contribute to immune suppression. LAIR1 is being targeted as a myeloid and stromal checkpoint in cancer immunotherapy.

ABOUT IO-106

IO-106 is a first-in-class monoclonal antibody that antagonizes LAIR1. It has broad potential in collagen-rich solid tumors and could be a candidate for combination therapy with PD-1 inhibitors and other immunotherapies. Preclinical research shows that IO-106 can reverse collagen-mediated immune suppression and mobilize anti-tumor immunity of multiple cell types including lymphocytes and myeloid cells. IO-106 entered into Investigational New Drug application (IND)-enabling studies with targeted IND submission in 1H2023.